Evidence mapPaperPMID 39672599Full record

ArticleThe Journal of clinical endocrinology and metabolism2025

Long-Acting Growth Hormone Therapy in Pediatric Growth Hormone Deficiency: A Consensus Statement.

Aristides Maniatis, Wayne Cutfield, Mehul Dattani, Cheri Deal, Paulo Ferrez Collett-Solberg, Reiko Horikawa, Mohamad Maghnie, Bradley S Miller, Michel Polak, Lars Sävendahl and 1 more

Erratum issuedAbstract readConsensus Statement
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Review
  3. Navepegritide in children with achondroplasia.Translational pediatrics · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Aristides ManiatisRocky Mountain Pediatric Endocrinology, Centennial, CO 80112, USA.ORCID 0000-0002-6705-8579
Wayne CutfieldLiggins Institute, University of Auckland, Auckland 1142, New Zealand.ORCID 0000-0001-6107-3682
Mehul DattaniGenetics and Genomic Medicine Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, London WC1N 1EH, UK.
Cheri DealCentre de recherche CHU Ste-Justine, Université de Montréal, Montréal H3T 1C5, Canada.
Paulo Ferrez Collett-SolbergDisciplina de Endocrinologia, Departamento de Medicina Interna, Faculdade de Ciências Medicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20550-170, Brazil.
Reiko HorikawaDivision of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo 157-8535, Japan.ORCID 0000-0003-3429-3246
Mohamad MaghnieDepartment of Pediatrics, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.ORCID 0000-0002-7183-5238
Bradley S MillerDivision of Endocrinology, Department of Pediatrics, University of Minnesota Medical School, M Health Fairview Masonic Children's Hospital, Minneapolis, MN 55454, USA.ORCID 0000-0003-3663-5473
Michel PolakService d'Endocrinologie, Gynécologie et Diabétologie Pédiatriques, Hôpital Universitaire Necker Enfants Malades, AP-HP, Université Paris Cité, 75015 Paris, France.
Lars SävendahlDivision of Pediatric Endocrinology, Department of Women's and Children's Health, Karolinska Institutet and Karolinska University Hospital, 171 77 Stockholm, Sweden.
Joachim WoelfleDepartment of Pediatrics and Adolescent Medicine, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg, 91054 Erlangen, Germany.

Funding

Pfizer Ltd
6 · The paper itself

Abstract

contextSeveral long-acting growth hormone (LAGH) therapies have recently become available, but guidance on their usage in children with growth hormone (GH) deficiency is limited.

methodsInternational experts in pediatric endocrinology were invited to join a consensus group based on their expertise in treating children with daily GH and LAGH. The group comprised 11 experts from 10 countries across the world. Online group meetings were held in February to March 2024 followed by a 1-day in-person meeting in May 2024 to finalize the consensus recommendations. A targeted literature search approach was used to identify and share evidence ahead of the meetings. Formulations considered were limited to those with international populations in phase III pivotal trials and regulatory approvals in multiple countries. EVIDENCE SYNTHESIS: Topics covered include patient selection and preference, dose adjustment, initiating and switching therapies, administration, adherence and missed doses, practical considerations, and knowledge gaps. LAGH formulations offer a potential advantage over daily GH injections for children with GH deficiency in terms of reduced injection frequency and treatment burden; this may also be associated with improved adherence and treatment outcomes over time. However, data on LAGH in pediatric GH deficiency are mostly limited to clinical trials, and long-term, real-world data are currently lacking.

conclusionThis article provides an international consensus on the use of LAGH therapy in children with GH deficiency to guide practitioners when considering these new treatment options for their patients. Long-term data are needed to fill current data gaps and allow the creation of comprehensive evidence-based recommendations.

Indexed as

Growth DisordersHormone Replacement TherapyHuman Growth HormoneChildConsensusDelayed-Action PreparationsHumansPractice Guidelines as TopicDelayed-Action PreparationsHuman Growth Hormonechildrenconsensusgrowth hormone deficiencylong-acting growth hormone therapypatient selection

Identifiers

PMID39672599
PMCPMC11913077

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.